# Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Canonical URL: https://biopharmsignal.com/news/COCP/cocrystal-pharma-to-present-at-the-noble-capital-markets-21st-emerging-growth-eq-705adce5
Ticker: COCP
Company: Cocrystal Pharma
Source: Cocrystal Pharma
Published: 2025-12-01 13:00 EST
## Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO...

## Article Body
Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21 st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.

Interested investors and guests of Cocrystal Pharma are welcome to attend the conference at a discounted rate. Please register here using the discount code COCPNOBLECON.

A video webcast of the Cocrystal presentation will be available on December 4, one day after the live event, on the Company's website and archived for 90 days.

About Noble Capital Markets, Inc. Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2018, Noble launched Channelchek —an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer investors free institutional-quality research without a subscription.

About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Contact: Alliance Advisors IR Jody Cain 310-691-7100 jcain@allianceadvisors.com

# # #
## Recent Company News
- 2026-06-03 11:00 EST — [Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer](https://biopharmsignal.com/news/COCP/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-with-extens-347ef789) — Source: Cocrystal Pharma
- 2026-05-26 12:00 EST — [Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza](https://biopharmsignal.com/news/COCP/cocrystal-pharma-announces-discovery-of-pan-viral-inhibitors-targeting-hantaviru-6c5d714e) — Source: Cocrystal Pharma
- 2026-05-15 12:00 EST — [Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/COCP/cocrystal-pharma-provides-business-update-and-reports-first-quarter-2026-financi-f400071b) — Source: Cocrystal Pharma
- 2026-04-30 20:05 EST — [Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection](https://biopharmsignal.com/news/COCP/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-cl-398ed2cd) — Source: Cocrystal Pharma
- 2026-04-02 12:00 EST — [Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive](https://biopharmsignal.com/news/COCP/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-i-185fbcc5) — Source: Cocrystal Pharma
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)